ImmunoLogic, Episode 7: "IL-9 and CAR-T Therapy” With Anusha Kalbasi, MD

We're excited to introduce another episode of the ImmunoLogic video podcast, hosted by Joseph Fraietta, PhD, an assistant professor of microbiology and the director of the Fraietta Lab at the University of Pennsylvania. Fraietta is joined by cohost Janna Minehart, MD, a clinical fellow in oncology (Master of Science Translational Research Program) at the University of Pennsylvania. Our hope is that this show will serve as a critical forum for clinicians, translational researchers, and biotechnology professionals to explore the evolving landscape of immunotherapy. We're seeking to bridge cutting-edge research with practical applications and delve into how immune-based therapies transition from innovative discoveries to transformative patient care solutions.

In this episode, the cohosts speak with Anusha Kalbasi, MD, an associate professor of radiation oncology (radiation therapy) at Stanford Medicine, about his recently published paper on the use of interleukin-9 (IL-9) to enhance chimeric antigen receptor T-cell (CAR-T) therapy efficacy without the need for lymphodepleting chemotherapy. Kalbasi, Fraietta, and Minehart cover topics including engineering T-cells to express the IL-9 receptor and use of native IL-9, clinical challenges, trial design, the use of IL-9 in solid tumors vesus hematologic malignancies, and open questions on cytokine signaling kinetics and host immune system interactions.

ImmunoLogic is tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility. This podcast is an essential resource for those driving the future of immunotherapy.

Interested in cohosting an episode or being a guest? Have feedback to share? If you'd like to get in touch to talk about the show, contact our editorial director, Matt Hoffman: [email protected].